ReviewPediatric pulmonology2018
Respiratory syncytial virus is an "opportunistic" killer.
Review in Pediatric pulmonology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Effect of Respiratory Syncytial Virus on the Global Burden of Lower Respiratory Infections: Lessons From the Global Burden of Disease Study 1990-2021.Immunity, inflammation and disease · 2026Article
- Wastewater-Based Surveillance of Respiratory Syncytial Virus Reveals a Temporal Disconnect in Disease Trajectory across an Active International Land Border.Environment & health (Washington, D.C.) · 2025Article
- Cost of illness due to respiratory syncytial virus acute lower respiratory tract infection among infants hospitalized in Argentina.BMC public health · 2024Article
- The impact of anthropogenic climate change on pediatric viral diseases.Pediatric research · 2024Review
- Time trend of respiratory viruses before and during the COVID-19 pandemic in severe acute respiratory virus infection in the Sultanate of Oman between 2017 and 2022.Influenza and other respiratory viruses · 2023Article
- Respiratory syncytial virus infection and novel interventions.Nature reviews. Microbiology · 2023Review
- Influenza and respiratory syncytial virus during the COVID-19 pandemic: Time for a new paradigm?Pediatric pulmonology · 2022Article
- Potential Neurocognitive Symptoms Due to Respiratory Syncytial Virus Infection.Pathogens (Basel, Switzerland) · 2021Review
- Uncovering Causes of Childhood Death Using the Minimally Invasive Autopsy at the Community Level in an Urban Vulnerable Setting of Argentina: A Population-Based Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- The cost-utility of early use of high-flow nasal cannula in bronchiolitis.Health economics review · 2021Article
- Community Mortality Due to Respiratory Syncytial Virus in Argentina: Population-based Surveillance Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021Article
- Article
- Seasonal variation and etiologic inferences of childhood pneumonia and diarrhea mortality in India.eLife · 2019Article
- Characterization of Pathogenic Sepsis Etiologies and Patient Profiles: A Novel Approach to Triage and Treatment.Microbiology insights · 2019Review
- Respiratory syncytial virus is an "opportunistic" killer.Pediatric pulmonology · 2018Review
- Viral Sepsis in Children.Frontiers in pediatrics · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV), responsible for more than three million yearly hospitalizations and up to 118 000 deaths in children under 5 years, is the leading pulmonary cause of death for this age group that lacks a licensed vaccine. Ninety-nine percent of deaths due to the virus occur in developing countries. In-hospital RSV fatalities affect previously healthy term infants in association with bacterial sepsis, clinically significant pneumothoraxes and, to a lesser extent, comorbid conditions. Community deaths affect low-income children from socially vulnerable families and appear to be as frequent as inpatient fatalities. In industrialized countries, RSV deaths occur almost exclusively in children with premorbid conditions. In a sense, RSV is an "opportunistic" killer. It needs a synergistic premorbid, medical practice-related, infectious, or social co-factor to cause a fatal outcome. But while the complex problems associated with these co-factors await solutions, candidate vaccines, long-lived monoclonal antibodies and antivirals against RSV are under clinical evaluation. It seems reasonable to predict that the landscape of RSV infections will look different in the next decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.